









Mercado
/
Acciones
/
nasdaq-akba
/

Akebia Therapeutics Inc

AKBA

2.040USD

+0.030+1.49%

Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min

536.61MCap. mercado

PérdidaP/E TTM



Akebia Therapeutics Inc

2.040

+0.030+1.49%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Akebia Therapeutics Inc Compañía

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Información de Akebia Therapeutics Inc



Símbolo de cotizaciónAKBA

Nombre de la empresaAkebia Therapeutics Inc

Fecha de salida a bolsaMar 20, 2014

Director ejecutivoMr. John P. Butler

Número de empleados181

Tipo de seguridadOrdinary Share

Fin del año fiscalMar 20

Dirección245 First Street

CiudadCAMBRIDGE

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal02142

Teléfono16178712098

Sitio Webhttps://akebia.com/

Símbolo de cotizaciónAKBA

Fecha de salida a bolsaMar 20, 2014

Director ejecutivoMr. John P. Butler

Ejecutivos de Akebia Therapeutics Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

Ms. Leanne M. Zumwalt

Independent Director

79.40K

+81.69%

Mr. Nicholas (Nik) Grund

Senior Vice President, Chief Commercial Officer

45.48K

-89.72%

Mr. Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer

-100.00%

Dr. Steven K. Burke, M.D.

Senior Vice President - Research and Development, Chief Medical Officer

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: mar., 19 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

6.25%

The Vanguard Group, Inc.

5.84%

State Street Investment Management (US)

3.02%

Geode Capital Management, L.L.C.

2.29%

Alerce Investment Management, L.P.

2.17%

Otro

80.43%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

6.25%

The Vanguard Group, Inc.

5.84%

State Street Investment Management (US)

3.02%

Geode Capital Management, L.L.C.

2.29%

Alerce Investment Management, L.P.

2.17%

Otro

80.43%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

17.20%

Investment Advisor/Hedge Fund

13.14%

Hedge Fund

7.04%

Research Firm

4.02%

Individual Investor

3.57%

Private Equity

2.17%

Bank and Trust

0.20%

Pension Fund

0.16%

Venture Capital

0.06%

Otro

52.45%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

299

117.08M

44.16%

+9.43M

2025Q2

284

112.41M

42.78%

+33.09M

2025Q1

280

111.54M

42.50%

+30.68M

2024Q4

258

78.54M

36.08%

+7.41M

2024Q3

257

64.16M

30.51%

-2.18M

2024Q2

248

61.31M

29.27%

-7.52M

2024Q1

290

61.37M

29.36%

-12.30M

2023Q4

289

58.79M

31.24%

-20.79M

2023Q3

300

57.28M

30.45%

-25.18M

2023Q2

308

56.18M

30.22%

-26.52M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

16.58M

6.25%

+2.61M

+18.71%

Jun 30, 2025

The Vanguard Group, Inc.

14.61M

5.51%

+1.93M

+15.18%

Jun 30, 2025

State Street Investment Management (US)

8.00M

3.02%

+1.19M

+17.50%

Jun 30, 2025

Geode Capital Management, L.L.C.

6.07M

2.29%

+1.04M

+20.75%

Jun 30, 2025

Alerce Investment Management, L.P.

5.75M

2.17%

Dec 31, 2024

Satter Muneer A

5.75M

2.17%

+5.75M

Dec 31, 2024

Morgan Stanley & Co. LLC

4.34M

1.64%

+2.26M

+108.33%

Jun 30, 2025

Renaissance Technologies LLC

4.19M

1.58%

+188.60K

+4.71%

Jun 30, 2025

Goldman Sachs & Company, Inc.

3.53M

1.33%

+1.07M

+43.71%

Jun 30, 2025

MPM BioImpact LLC

2.89M

1.09%

+2.89M

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

Invesco Biotechnology & Genome ETF

2.36%

Invesco NASDAQ Future Gen 200 ETF

0.42%

ALPS Medical Breakthroughs ETF

0.42%

SPDR S&P Biotech ETF

0.34%

Federated Hermes MDT Small Cap Core ETF

0.2%

Direxion Daily S&P Biotech Bull 3X Shares

0.18%

iShares Micro-Cap ETF

0.13%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.11%

Vanguard US Momentum Factor ETF

0.1%

Fidelity Enhanced Small Cap ETF

0.09%

Invesco Biotechnology & Genome ETF

Proporción2.36%

Invesco NASDAQ Future Gen 200 ETF

Proporción0.42%

ALPS Medical Breakthroughs ETF

Proporción0.42%

SPDR S&P Biotech ETF

Proporción0.34%

Federated Hermes MDT Small Cap Core ETF

Proporción0.2%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.18%

iShares Micro-Cap ETF

Proporción0.13%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proporción0.11%

Vanguard US Momentum Factor ETF

Proporción0.1%

Fidelity Enhanced Small Cap ETF

Proporción0.09%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

